Tango Therapeutics

Associate Medical Director, Pharmacovigilance

Tango Therapeutics  •  $194k - $292k/yr  •  Boston, MA (Onsite)  •  2 hours ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.

This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.

The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.

The Medical Director/Medical Reviewer, Pharmacovigilance will be responsible to perform medical review and assessment of Individual Case Safety Reports (ICSRs) and provide medical oversight. The Medical Reviewer will ensure clinical accuracy, consistency, quality, and compliance with applicable pharmacovigilance requirements.

Your Role

Perform Medical Review activities

  • Review ICSRs from clinical trials, literature, solicited programs, and other sources
  • Assess adverse events for seriousness, causality, expectedness/listedness, and clinical significance per regulations and company procedures
  • Evaluate case details for medical consistency, including demographics, history, medications, labs, treatment, course, and outcomes
  • Review and validate MedDRA coding, diagnoses, events, indications, and relevant medical data
  • Assess temporal relationships, de-challenge/rechallenge, alternative etiologies, risk factors, and outcomes, as applicable
  • Review, edit, and approve ICSR narratives for accuracy, completeness, concision, and clinical coherence
  • Author robust and medically sound company comments for ICSRs, clearly documenting the company's medical assessment, clinical rationale, causality considerations, relevant medical history, alternative etiologies, and overall safety evaluation, as applicable
  • Review queries, identify key missing information, and recommend appropriate case follow-up queries
  • Ensure proper documentation and escalation of significant safety information
  • Review vendor-created AOSEs/AOSE search terms for medical accuracy, completeness, consistency, and appropriateness
  • Escalate medically significant cases and potential safety concerns to appropriate stakeholders
  • Provide medical guidance to the vendor on findings and recurring quality issues
  • Monitor quality and consistency, identifying trends that require training or process improvement
  • Provide vendor guidance and feedback to maintain consistent ICSR quality
  • Support activities related to creation or maintenance of PV procedures, medical review guidelines, AOSE criteria, training materials, quality metrics and other relevant activities
  • Provide medical oversight of vendor-performed ICSR activities
  • Review vendor deliverables for quality, accuracy, completeness, and timeliness
  • Identify recurring medical review quality issues and share findings with the vendor
  • Support vendor training and clarify medical review expectations, as needed
  • Contribute to vendor performance monitoring and quality improvement
  • Complete other ad hoc activities as assigned

What You Bring

  • 4+ years of total relevant experience in Pharmacovigilance/Drug Safety, Clinical Research, or a related area. 2–5 years of hands-on ICSR medical review experience is preferred
  • MD/DO/Foreign Medical Graduate or equivalent clinical/medical qualification
  • Relevant experience in Pharmacovigilance, Drug Safety, Clinical Research
  • Hands-on experience in ICSR medical review and case assessment
  • Experience reviewing AOSEs or other safety surveillance assessments is preferred
  • Good understanding of ICH, GVP, FDA, EMA, and applicable pharmacovigilance requirements
  • Working knowledge of WHO drug and MedDRA terminology and coding principles
  • Strong clinical assessment, analytical, medical writing, and communication skills
  • Ability to independently assess complex clinical cases and make sound medical judgments
  • Excellent communication and cross-functional collaboration skills

We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

Salary range
$194,400$291,600 USD
Tango Therapeutics

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.

Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion.

What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity.

Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.

Industry
Biotech & Life Sciences
Company Size
51-200 employees
Headquarters
Boston, Massachusetts
Year Founded
2017
Social Media